These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 8493922)

  • 21. Diversity in developmental actions of androgens.
    Hughes IA
    Clin Endocrinol (Oxf); 2001 Jun; 54(6):707-8. PubMed ID: 11422103
    [No Abstract]   [Full Text] [Related]  

  • 22. An examination of how different mutations at arginine 855 of the androgen receptor result in different androgen insensitivity phenotypes.
    Elhaji YA; Wu JH; Gottlieb B; Beitel LK; Alvarado C; Batist G; Trifiro MA
    Mol Endocrinol; 2004 Aug; 18(8):1876-86. PubMed ID: 15118070
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Androgen insensitivity syndrome.
    Mongan NP; Tadokoro-Cuccaro R; Bunch T; Hughes IA
    Best Pract Res Clin Endocrinol Metab; 2015 Aug; 29(4):569-80. PubMed ID: 26303084
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The cytosolic aldehyde dehydrogenase gene (Aldh1) is developmentally expressed in Leydig cells.
    López-Fernández LA; del Mazo J
    FEBS Lett; 1997 Apr; 407(2):225-9. PubMed ID: 9166904
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Complete androgen insensitivity syndrome characterized by increased concentration of a normal androgen receptor in genital skin fibroblasts.
    Hughes IA; Evans BA
    J Clin Endocrinol Metab; 1986 Aug; 63(2):309-15. PubMed ID: 3088020
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Human complete androgen insensitivity with normal dihydrotestosterone receptor binding capacity in cultured genital skin fibroblasts: evidence for a qualitative abnormality of the receptor.
    Brown TR; Maes M; Rothwell SW; Migeon CJ
    J Clin Endocrinol Metab; 1982 Jul; 55(1):61-9. PubMed ID: 7076808
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Long-term followup and comparison between genotype and phenotype in 29 cases of complete androgen insensitivity syndrome.
    Cheikhelard A; Morel Y; Thibaud E; Lortat-Jacob S; Jaubert F; Polak M; Nihoul-Fekete C
    J Urol; 2008 Oct; 180(4):1496-501. PubMed ID: 18710728
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Autoradiographic binding studies with [3H]oestradiol and [3H]dihydrotestosterone in the autonomic genital ganglion (plexus of Frankenhäuser) of the mouse.
    Schleicher G; Stumpf WE; Thiedemann KU; Drews U
    Acta Endocrinol (Copenh); 1985 Dec; 110(4):572-6. PubMed ID: 4090917
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Complete androgen insensitivity with a normal amount of 5 alpha-dihydrotestosterone-binding activity in labium majus skin fibroblasts.
    Kaufman M; Pinsky L; Baird PA; McGillivray BC
    Am J Med Genet; 1979; 4(4):401-11. PubMed ID: 575468
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Proceedings: Testicular feminization: studies of the molecular basis of a genetic defect.
    Bardin CW; Bullock LP
    J Invest Dermatol; 1974 Jul; 63(1):75-84. PubMed ID: 4601131
    [No Abstract]   [Full Text] [Related]  

  • 31. Testicular feminization associated with a thermolabile androgen receptor in culutred human fibroblasts.
    Griffin JE
    J Clin Invest; 1979 Dec; 64(6):1624-31. PubMed ID: 500829
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Genetic basis of endocrine disease. 4. The spectrum of mutations in the androgen receptor gene that causes androgen resistance.
    McPhaul MJ; Marcelli M; Zoppi S; Griffin JE; Wilson JD
    J Clin Endocrinol Metab; 1993 Jan; 76(1):17-23. PubMed ID: 8421085
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Differential diagnosis and treatment of girls with 46XY-karyotype and androgen insensitivity syndrome].
    Drop SL; Boehmer AL; Slijper FM; Nijman JM; Hazebroek FW; Niermeijer MF
    Ned Tijdschr Geneeskd; 2001 Apr; 145(14):665-9. PubMed ID: 11530701
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A role for the androgen receptor in collagen content of the skin.
    Markova MS; Zeskand J; McEntee B; Rothstein J; Jimenez SA; Siracusa LD
    J Invest Dermatol; 2004 Dec; 123(6):1052-6. PubMed ID: 15610513
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparison of the molecular consequences of different mutations at residue 754 and 690 of the androgen receptor (AR) and androgen insensitivity syndrome (AIS) phenotype.
    Tadokoro R; Bunch T; Schwabe JW; Hughes IA; Murphy JC
    Clin Endocrinol (Oxf); 2009 Aug; 71(2):253-60. PubMed ID: 19178528
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Syndromes of resistance to androgens].
    Kuttenn F; Mowszowicz J; Wright F
    Ann Endocrinol (Paris); 1983; 44(5):327-31. PubMed ID: 6372640
    [No Abstract]   [Full Text] [Related]  

  • 37. Androgen insensitivity syndrome: gonadal androgen receptor activity.
    Coulam CB; Graham ML; Spelsberg TC
    Am J Obstet Gynecol; 1984 Nov; 150(5 Pt 1):531-3. PubMed ID: 6333820
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Complete androgen insensitivity without Wolffian duct development: the AR-A form of the androgen receptor is not sufficient for male genital development.
    Barbaro M; Oscarson M; Almskog I; Hamberg H; Wedell A
    Clin Endocrinol (Oxf); 2007 Jun; 66(6):822-6. PubMed ID: 17408421
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Defective androgen action at the cellular level in the androgen resistance syndromes. I. Differences between the complete and incomplete testicular feminization syndromes.
    Medina M; Chávez B; Pérez-Palacios G
    J Clin Endocrinol Metab; 1981 Dec; 53(6):1243-6. PubMed ID: 7298803
    [No Abstract]   [Full Text] [Related]  

  • 40. Amino acid substitutions in the hormone-binding domain of the human androgen receptor alter the stability of the hormone receptor complex.
    Marcelli M; Zoppi S; Wilson CM; Griffin JE; McPhaul MJ
    J Clin Invest; 1994 Oct; 94(4):1642-50. PubMed ID: 7929841
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.